Oncotarget

Research Papers:

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition

Aurélia Nguyen, François Marie Moussalieh, Alan Mackay, A. Ercument Cicek, Andres Coca, Marie Pierre Chenard, Noelle Weingertner, Benoit Lhermitte, Eric Letouzé, Eric Guérin, Erwan Pencreach, Sarah Jannier, Dominique Guenot, Izzie Jacques Namer, Chris Jones and Natacha Entz-Werlé _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:71597-71617. https://doi.org/10.18632/oncotarget.16500

Metrics: PDF 1825 views  |   HTML 2295 views  |   ?  


Abstract

Aurélia Nguyen1, François Marie Moussallieh2,*, Alan Mackay3,*, A. Ercument Cicek4,5, Andres Coca6, Marie Pierre Chenard7,8, Noelle Weingertner7, Benoit Lhermitte7, Eric Letouzé9, Eric Guérin1, Erwan Pencreach1, Sarah Jannier1,10, Dominique Guenot1, Izzie Jacques Namer2, Chris Jones3 and Natacha Entz-Werlé1,10

1Laboratory EA 3430, Progression Tumorale et Micro-Environnement, Approches Translationnelles et Epidémiologie, University of Strasbourg, Strasbourg, France

2Department of Nuclear Medicine, University Hospital of Strasbourg, Strasbourg, France

3Institute of Cancer Research, Sutton, Surrey, United Kingdom

4Computational Biology Department, Carnegie Mellon University, Pittsburgh, PA, USA

5Computer Engineering Department, Bilkent University, Cankaya, Ankara, Turkey

6Department of Neurosurgery, University Hospital of Strasbourg, Strasbourg, France

7Department of Pathology, University Hospital of Strasbourg, Strasbourg, France

8Centre de Ressources Biologiques, University Hospital of Strasbourg, Strasbourg, France

9Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre Le Cancer, Paris, France

10Department of Pediatric Onco-hematology, University Hospital of Strasbourg, Strasbourg, France

*These authors have contributed equally to this work

Correspondence to:

Natacha Entz-Werlé, email: Natacha.entz-werle@chru-strasbourg.fr

Keywords: high grade glioma, pediatric, HIF1alpha, mTor, targets

Received: June 14, 2016     Accepted: January 16, 2017     Published: March 23, 2017

ABSTRACT

Pediatric high grade glioma (pHGGs), including sus-tentorial and diffuse intrinsic pontine gliomas, are known to have a very dismal prognosis. For instance, even an increased knowledge on molecular biology driving this brain tumor entity, there is no treatment able to cure those patients. Therefore, we were focusing on a translational pathway able to increase the cell resistance to treatment and to reprogram metabolically tumor cells, which are, then, adapting easily to a hypoxic microenvironment. To establish, the crucial role of the hypoxic pathways in pHGGs, we, first, assessed their protein and transcriptomic deregulations in a pediatric cohort of pHGGs and in pHGG’s cell lines, cultured in both normoxic and hypoxic conditions. Secondly, based on the concept of a bi-therapy targeting in pHGGs mTORC1 (rapamycin) and HIF-1α (irinotecan), we hypothesized that the balanced expressions between RAS/ERK, PI3K/AKT and HIF-1α/HIF-2α/MYC proteins or genes may provide a modulation of the cell response to this double targeting. Finally, we could evidence three protein, genomic and metabolomic profiles of response to rapamycin combined with irinotecan. The pattern of highly sensitive cells to mTOR/HIF-1α targeting was linked to a MYC/ERK/HIF-1α over-expression and the cell resistance to a major hyper-expression of HIF-2α.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16500